Aurora Cannabis (TSE:ACB) has released an update.
Aurora Cannabis reported impressive fiscal 2025 second-quarter results, achieving a record adjusted EBITDA of $10.1 million, marking a 210% increase year-over-year. The company saw a 29% rise in net revenue to $81.1 million, driven by strong growth in its global medical cannabis sector, particularly in markets like Australia and Germany. Aurora also maintained a robust balance sheet with significant cash reserves and a debt-free cannabis operation.
For further insights into TSE:ACB stock, check out TipRanks’ Stock Analysis page.
